Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
Unlabelled: Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become an important tool to predict favorable outcome. We sought to investigate the impact of relative changes of BCR-ABL transcript levels within the initial 3 months of therapy. In order to achieve accu...
| Publicado en: | Leukemia (08876924) Vol. 28; no. 10; pp. 1988 - 1993 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | research randomized controlled trial Journal Article |
| Publicado: |
Springer Nature
Oct2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103849605&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 103849605 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 08876924 DZG jtl: Leukemia (08876924) issn: 08876924 maglogo: Y pubinfo: dt: Oct2014 vid: 28 iid: 10 pid: 2579 pub: Springer Nature place: Dordrecht, <Blank> artinfo: ui: 103849605 NLM24798484 2012761099 10.1038/leu.2014.153 NLM24798484 103849605 ppf: 1988 ppct: 5 formats: tig: atl: Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. aug: au: Hanfstein, B Shlyakhto, V Lauseker, M Hehlmann, R Saussele, S Dietz, C Erben, P Fabarius, A Proetel, U Schnittger, S Krause, S W Schubert, J Einsele, H Hänel, M Dengler, J Falge, C Kanz, L Neubauer, A Kneba, M Stegelmann, F sug: subj: Antineoplastic Agents Therapeutic Use Benzamides Therapeutic Use Proteins Metabolism Leukemia, Myeloid, Chronic Drug Therapy Leukemia, Myeloid, Chronic Heterocyclic Compounds Therapeutic Use Adolescence Adult Aged Aged, 80 and Over Prognosis Female Glycoside Hydrolases Metabolism Human Leukemia, Myeloid, Chronic Metabolism Male Middle Age Cox Proportional Hazards Model Relative Risk Sensitivity and Specificity Treatment Outcomes Young Adult Adolescent: 13-18 years Adult: 19-44 years Aged: 65+ years Aged, 80 & over Middle Aged: 45-64 years Female Male ab: Unlabelled: Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become an important tool to predict favorable outcome. We sought to investigate the impact of relative changes of BCR-ABL transcript levels within the initial 3 months of therapy. In order to achieve accurate data for high BCR-ABL levels at diagnosis, beta glucuronidase (GUS) was used as a reference gene. Within the German CML-Study IV, samples of 408 imatinib-treated patients were available in a single laboratory for both times, diagnosis and 3 months on treatment. In total, 301 of these were treatment-naïve at sample collection.Results: (i) with regard to absolute transcript levels at diagnosis, no predictive cutoff could be identified; (ii) at 3 months, an individual reduction of BCR-ABL transcripts to the 0.35-fold of baseline level (0.46-log reduction, that is, roughly half-log) separated best (high risk: 16% of patients, 5-year overall survival (OS) 83% vs 98%, hazard ratio (HR) 6.3, P=0.001); (iii) at 3 months, a 6% BCR-ABL(IS) cutoff derived from BCR-ABL/GUS yielded a good and sensitive discrimination (high risk: 22% of patients, 5-year OS 85% vs 98%, HR 6.1, P=0.002). Patients at risk of disease progression can be identified precisely by the lack of a half-log reduction of BCR-ABL transcripts at 3 months. pubtype: Academic Journal doctype: research randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|